Primary Tumor Epigenetic and Transcriptomic Alterations Associated with Nodal Burden and Metastatic Risk in ER+/HER2− Breast Cancer
Authors:
Open Access
- 4 September 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (17) , 7901
Abstract
De-escalation of axillary surgery has resulted in the loss of pathologic nodal information, yet the extent of lymph node involvement remains an important determinant of treatment decisions in estrogen receptor-positive (ER+)/HER2− disease. We examined whether primary tumors differed molecularly according to the extent of this regional dissemination. Genome-wide DNA methylation profiling of primary ER+/HER2− tumors from 47 patients with pN1 (n = 29) vs. >pN1 (n = 18) disease showed differences concentrated at promoters of developmental and cell-adhesion genes. By integrating methylomes with transcriptomes from the TCGA-BRCA cohort (n = 148) and clinical outcomes from KM Plotter (RFS, n = 1154; OS, n = 442; DMFS, n = 423), we identified four genes (ARL10, RIC3, CXCL14, KCNH2) showing concordant molecular and clinical associations, from which we derived the Lymph-node Involvement Outcome Numerator (LION) score. Lower LION scores were observed in metastatic lesions from the AURORA US cohort (n = 45). In SCAN-B (n = 3969), lower scores were associated with shorter distant recurrence-free intervals (HR = 0.38; 95% CI 0.23–0.62); this association persisted after adjustment for age, nodal and tumor category but was lost after adjustment for histological grade (HR = 0.83; 95% CI 0.48–1.44), indicating that the score and grade capture overlapping biology. These findings suggest that primary tumors already display coordinated epigenetic and transcriptional alterations associated with the extent of metastatic dissemination.Keywords
Funding Information
- U.S. Department of War (HT9425-23-1-0030)
- Duke University BioRepository & Precision Pathology Center (P30CA014236)
- National Cancer Institute (RRID: SCR_004446)
- Duke University (UM1CA239755)
- Govern de les Illes Balears (POSTDOC001)
- Govern de les Illes Balears (#FPI/037/2021)
- Spanish Association Against Cancer (PRDPM246418BEDO)
- Balearic Islands Government FPI program (#FPI/037/2021)
- CEP/EDUIB-Santander mobility
This publication has 51 references indexed in Scilit:
- CADONOT: Comparing axillary dissection or not in breast cancer surgeryThe Breast, 2025
- Epigenetic regulation of breast cancer metastasisCancer and Metastasis Reviews, 2023
- Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancerBreast Cancer Research and Treatment, 2022
- Chemokine CXCL14; a double-edged sword in cancer developmentInternational Immunopharmacology, 2021
- Prognostic biomarker identification and tumor classification in breast cancer patients by methylation and transcriptome analysisFEBS Open Bio, 2021
- RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammationInternational Immunopharmacology, 2020
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2017
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trialThe Lancet Oncology, 2014
- Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23–01): a phase 3 randomised controlled trialThe Lancet Oncology, 2013
- Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node MetastasisJAMA, 2011